Yin Hanlin, Wan Qin
Endocrine Thyroid Disease Center, Deyang People's Hospital, Deyang City, Sichuan Province, China.
Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou City, Sichuan Province, China.
Anatol J Cardiol. 2024 Sep 18;28(11):533-41. doi: 10.14744/AnatolJCardiol.2024.4582.
The aim is to investigate the clinical efficacy of Alprostadil in diabetes mellitus (DM) combined with peripheral atherosclerosis and to investigate the molecular mechanisms.
Patients included 154 cases with DM combined with peripheral atherosclerosis and were divided into the conventional group (77 cases) and the Alprostadil group (77 cases). Both groups of patients were given conventional treatment, and the Alprostadil group was given Alprostadil treatment on the basis of the conventional group. The therapeutic efficacy and clinical symptom improvement were compared, and the adverse reactions were observed. An in vitro cell model was constructed using high glucose (HG) (50 mM) and oxidized low-density lipoprotein (50 μg/mL) treatment.
The total effective rate of treatment in the Alprostadil group was higher than that in the conventional group. The biochemical indices of whole blood viscosity, plasma viscosity, erythrocyte pressure volume, and fibrinogen, as well as the level of inflammatory factors in the Alprostadil group were lower than those in the conventional group. The incidence rate of adverse reactions of Alprostadil administration was lower than that in the conventional group (P = .030). Alprostadil inhibited platelet aggregation and promoted platelet spreading. Alprostadil had an ameliorative effect on HG- and oxidized low-density lipoprotein cholesterol (ox-LDL)-induced human umbilical vascular endothelial cells (HUVECs), and promoted apoptosis and inflammatory response of HUVECs.
Clinically, the use of Alprostadil as an adjunct to conventional therapy for the treatment of DM combined with peripheral atherosclerosis has high clinical efficacy. In addition, Alprostadil has a significant ameliorative effect on high glucose- and ox-LDL-induced HUVECs.
旨在探讨前列地尔治疗糖尿病（DM）合并周围动脉粥样硬化的临床疗效，并研究其分子机制。
选取154例DM合并周围动脉粥样硬化患者，分为常规组（77例）和前列地尔组（77例）。两组患者均给予常规治疗，前列地尔组在常规治疗基础上加用前列地尔治疗。比较两组治疗效果及临床症状改善情况，并观察不良反应。采用高糖（HG）（50 mM）和氧化型低密度脂蛋白（50 μg/mL）处理构建体外细胞模型。
前列地尔组治疗总有效率高于常规组。前列地尔组全血黏度、血浆黏度、红细胞压积、纤维蛋白原等生化指标以及炎症因子水平均低于常规组。前列地尔给药不良反应发生率低于常规组（P = 0.030）。前列地尔抑制血小板聚集并促进血小板铺展。前列地尔对HG和氧化型低密度脂蛋白胆固醇（ox-LDL）诱导的人脐静脉血管内皮细胞（HUVECs）有改善作用，并促进HUVECs的凋亡和炎症反应。
临床上，前列地尔作为常规治疗的辅助药物用于治疗DM合并周围动脉粥样硬化具有较高的临床疗效。此外，前列地尔对高糖和ox-LDL诱导的HUVECs有显著改善作用。
